Abstract
Clinical trials often report surrogate endpoint data. A surrogate endpoint is a biological marker or clinical sign that can be substituted for a patient-important outcome. Using surrogate endpoints correctly may facilitate and expedite clinical trials and may improve medical decisions. However, rigorous criteria must be met for an endpoint to be considered a valid surrogate. The purpose of this article is to review the topic of surrogate endpoints in the context of a urologic encounter.
Original language | English (US) |
---|---|
Pages (from-to) | 447-453 |
Number of pages | 7 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 29 |
Issue number | 4 |
DOIs | |
State | Published - Jul 2011 |
Keywords
- Biological Markers
- Data Interpretation
- Evidence-based medicine
- Surrogate endpoints
ASJC Scopus subject areas
- Oncology
- Urology